Moreover, the p38 inhibitors have demonstrated the capability to improve key lung function parameters and alleviate dyspnea in COPD patients, as assessed through measurements such as forced expiratory volume in 1 s (FEV1), forced vital capacity (FVC), and transition dyspnea index (TDI) [175]. Here, MAPK1 is linked to chronic obstructive pulmonary disease.